All News

Found 532 articles

• FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - March 11, 2019

  3/11/2019

  In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin

• New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community

  3/11/2019

  Represents first tranche to be released; data from all 500,000 UK Biobank participants will ultimately be made available via larger biopharma consortium effort

• CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication

  3/1/2019

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent® in asthma.

• New Analyses to Be Presented at AAD for Dupixent® (dupilumab) and the Burden of Atopic Dermatitis

  3/1/2019

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the companies will present a diverse set of clinical and real-world data at the 2019 American Academy of Dermatology Annual Meeting from March 1 to 5 in Washington, D.C.

• Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

  2/25/2019

  Dupixent showed significant improvement on every primary and secondary endpoint in patients with severe CRSwNP who had failed previous treatment with surgery and/or systemic corticosteroids

• U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor

  2/15/2019

  Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R)

• Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

  2/11/2019

  This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

• Regeneron and Sanofi Offer Praluent® (alirocumab) at a New Reduced U.S. List Price

  2/11/2019

  This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

• One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

  2/9/2019

  Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious vision-threatening complications

• 

  Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

  2/7/2019

  Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (...

• Sanofi delivers 2018 business EPS growth of 5.1% at CER

  2/7/2019

  Net sales were €8,997 million, an increase of 3.5% on a reported basis, 3.9%(3) at CER and 2.6% at CER/CS (4).

• Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

  2/6/2019

  Regeneron Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year 2018 and provided a business update.

• Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

  1/7/2019

  Companies select two clinical-stage bispecific antibodies for ongoing collaboration

• Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference

  1/7/2019

  Regeneron Pharmaceuticals, Inc. will provide a strategic business update to the investor community at the 37th Annual J.P. Morgan Healthcare Conference

• Harbour BioMed Appoints Atul Deshpande, Ph.D. MBA, Chief Strategy Officer and Head of U.S. Operations

  1/4/2019

  Company also promotes Xiaoxiang Chen, MD, to Chief Development Officer, and Mai-Jing Liao, Ph.D., MBA to Chief Business Officer

• United Neuroscience Names Peter Powchik, M.D, Executive Vice President of Research & Development

  12/21/2018

  United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced the appointment of Peter Powchik, M.D., to the newly created position of Executive Vice President of Research & Development effective Jan. 1, 2019.

• Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

  12/1/2018

  100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979

• ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause

  11/11/2018

  Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

• New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

  11/7/2018

  Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)

• FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis

  11/6/2018

  Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.